Summary of the Conference Call Industry or Company Involved - The conference call pertains to the **Jilin Province listed companies** and their efforts to enhance investor confidence through an online collective reception day event in 2025 [1][10]. Core Points and Arguments - The event is organized by the **Jilin Securities Industry Association** in collaboration with **Shenzhen Panorama Network Co., Ltd.**, aimed at improving the intellectual level of listed companies in Jilin and establishing a good communication mechanism between companies and investors [1][10]. - High-level executives from various listed companies, including chairpersons, general managers, financial directors, and board secretaries, participated in the online interaction with investors, addressing concerns regarding the **2024 annual reports**, risk prevention, investor protection, and sustainable development [1][10]. - The event utilized internet virtual space for face-to-face communication, allowing investors to gain a comprehensive understanding of the participating companies [3][10]. - A total of **872 questions** were answered by company representatives during the event, indicating a strong interaction between listed companies and investors [10]. Other Important but Possibly Overlooked Content - The event emphasized the importance of maintaining open channels for communication between listed companies and investors, encouraging ongoing dialogue beyond the event [10]. - The initiative reflects a broader trend in the industry towards enhancing transparency and responsiveness to investor inquiries, which is crucial for building trust and confidence in the market [1][10].

证券代码：002566 证券简称：益盛药业 公告编号：2024-026 吉林省集安益盛药业股份有限公司 第八届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 吉林省集安益盛药业股份有限公司（以下称"公司"）第八届董事会第十五 次会议通知以当面送达、电话、邮件的方式于2024年10月18日向各董事发出，会 议于2024年10月25日以现场会议的方式在公司四楼会议室召开。会议应参加审议 董事9人，实际参加审议董事9人。本次会议的召开符合《公司法》及《公司章程》 的规定，合法有效。会议由董事长张益胜先生主持，审议并通过了如下议案： 四、备查文件 公司第八届董事会第十五次会议决议。 特此公告。 吉林省集安益盛药业股份有限公司董事会 一、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《2024年 第三季度报告》。 《2024年第三季度报告》详见巨潮资讯网（www.cninfo.com.cn）及《中国 证券报》、《上海证券报》、《证券时报》。 二、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《关于向 银行申请流动资金贷款 ...

证券代码：002566 证券简称：益盛药业 公告编号：2024-027 吉林省集安益盛药业股份有限公司 第八届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 吉林省集安益盛药业股份有限公司（以下称"公司"）第八届监事会第十五 次会议通知以当面送达、电话的方式于2024年10月18日向各监事发出，会议于 2024年10月25日以现场会议方式在公司四楼会议室召开。会议应当出席的监事3 人，实际出席的监事3人。本次会议的召集、召开程序符合《公司法》等有关法 律、法规及《公司章程》的规定。会议由监事会主席于晓静女士主持，审议并通 过了如下议案： 一、会议以3票同意、0票反对、0票弃权的表决结果，审议通过了《2024年 第三季度报告》。 经审核，监事会认为董事会编制和审核公司2024年第三季度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 二、备查文件 公司第八届监事会第十五次会议决议。 特此公告。 吉林省集安益盛药业股份有限公司监事会 二 ...

证券代码：002566 证券简称：益盛药业 公告编号：2024-029 吉林省集安益盛药业股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2024 年第一次临时股东大会。 2、股东大会的召集人：公司董事会。2024年10月25日，公司第八届董事会 第十五次会议审议通过了《关于召开2024年第一次临时股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和公司章程的有关规定。 4、会议召开的日期、时间： 现场会议召开时间：2024 年 11 月 15 日（星期三）下午 14:30。 网络投票时间：2024 年 11 月 15 日。 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 11 月 15 日上午 9:15—9:25,9:30-11:30，下午 13:00-15:00；通过深圳证券交易所 互联网投票的具体时间为 2024 年 11 月 15 日 9:15-15:00 期间 ...

Financial Performance - The company's revenue for Q3 2024 was ¥157,716,894.39, representing a decrease of 13.21% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥2,528,970.69, down 77.10% year-over-year[2] - The net profit after deducting non-recurring gains and losses was -¥106,989.34, a decline of 101.43% compared to the previous year[2] - Total operating revenue for Q3 2024 was CNY 505.56 million, a decrease of 22.36% compared to CNY 651.15 million in the same period last year[14] - Net profit for Q3 2024 was CNY 33.40 million, a decline of 44.66% compared to CNY 60.20 million in Q3 2023[15] - Total comprehensive income for the period was CNY 33,402,435.53, compared to CNY 60,199,120.13 in the previous period, reflecting a decrease of approximately 44.6%[16] - Basic and diluted earnings per share were both CNY 0.1084, down from CNY 0.1767 in the previous period, indicating a decline of about 38.6%[16] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥41,175,388.85, down 74.64% year-over-year[2] - Cash inflow from operating activities totaled CNY 600,832,070.69, a decrease of 24.5% from CNY 796,571,102.42 in the previous period[17] - Net cash flow from operating activities was CNY 41,175,388.85, down 74.7% from CNY 162,346,702.32 in the previous period[17] - Cash outflow from investment activities was CNY 460,945,934.21, significantly higher than CNY 131,973,313.16 in the previous period[18] - Net cash flow from investment activities was -CNY 355,688,058.84, compared to -CNY 70,053,976.65 in the previous period, indicating a worsening investment position[18] - Cash inflow from financing activities was CNY 600,000,000.00, an increase from CNY 520,000,000.00 in the previous period[18] - Net cash flow from financing activities was -CNY 64,312,218.07, compared to a positive CNY 10,466,175.11 in the previous period, showing a shift to a net outflow[18] - The ending balance of cash and cash equivalents was CNY 108,908,752.89, down from CNY 446,022,778.54 in the previous period, reflecting a decrease of approximately 75.6%[18] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥3,004,867,731.15, a decrease of 1.37% from the end of the previous year[3] - The company's total assets as of Q3 2024 were CNY 3.00 billion, a decrease from CNY 3.05 billion at the end of the previous year[13] - Total liabilities decreased to CNY 688.69 million in Q3 2024 from CNY 714.30 million in the same period last year[13] - Shareholders' equity attributable to the parent company was ¥2,219,385,374.40, down 0.62% from the previous year-end[3] - The company's equity attributable to shareholders was CNY 2.22 billion, down from CNY 2.23 billion year-over-year[13] Investments and Financial Assets - The company reported a significant increase in trading financial assets, which rose by 320.70% to ¥433,245,468.90[7] - Investment income increased by 156.11% to ¥4,793,304.18, driven by higher returns from financial products[7] - The company reported an investment income of CNY 4.79 million for Q3 2024, compared to CNY 1.87 million in the previous year[15] - The company's trading financial assets increased significantly from 102,982,228.44 CNY to 433,245,468.90 CNY[10] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,678[8] - Zhang Yisheng holds 39.08% of shares, totaling 129,348,530 shares[8] Regulatory and Governance Issues - The company is addressing issues related to shareholding transparency and has a plan for reducing shareholding discrepancies[9] - Liu Jianming is in the process of reducing his held shares to ensure accurate information disclosure[10] - The company has received regulatory notifications regarding past shareholding issues and is implementing corrective measures[9] Operating Costs and Expenses - Total operating costs for Q3 2024 were CNY 487.97 million, down 18.69% from CNY 600.42 million year-over-year[14] - Research and development expenses for Q3 2024 amounted to CNY 14.38 million, slightly down from CNY 15.35 million in the previous year[14] - Financial expenses surged by 1945.90% to ¥4,351,479.19, primarily due to a decrease in interest income from agreement deposits[7] Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters[12]

证券代码：002566 证券简称：益盛药业 公告编号：2024-025 吉林省集安益盛药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省集安益盛药业股份有限公司（以下简称"公司"）于 2024 年 5 月 20 日召开第八届董事会第十三次会议、第八届监事会第十三次会议，审议通过了《关 于使用闲置自有资金购买理财产品的议案》，为提高公司资金使用效率，合理利 用闲置自有资金，在保证日常经营资金需求和资金安全的前提下，公司及子公司 使用不超过 35,000 万元人民币的闲置自有资金购买理财产品。内容详见公司于 2024 年 5 月 21 日在指定信息披露媒体及巨潮资讯网（www.cninfo.com.cn）披 露的《关于使用闲置自有资金购买理财产品的公告》（公告编号 2024-019）。 根据上述决议，公司使用 7,000 万元人民币闲置自有资金购买了方正证券股 份有限公司理财产品，将具体情况公告如下： 一、本次使用闲置自有资金购买理财产品的基本情况 1、公司与方正证券股份有限公司签署了《方正证券稳盛 ...

证券代码：002566 证券简称：益盛药业 公告编号：2024-024 吉林省集安益盛药业股份有限公司 关于使用闲置自有资金购买理财产品到期赎回的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省集安益盛药业股份有限公司（以下简称"公司"）于 2024 年 4 月 1 日召开第八届董事会第十次会议、第八届监事会第十次会议，审议通过了《关于 使用闲置自有资金购买理财产品的议案》，为提高公司资金使用效率，合理利用 闲置自有资金，在保证日常经营资金需求和资金安全的前提下，公司使用不超过 15,000 万元人民币的闲置自有资金购买理财产品。内容详见公司于 2024 年 4 月 2 日在指定信息披露媒体及巨潮资讯网（www.cninfo.com.cn）披露的《关于使 用闲置自有资金购买理财产品的公告》（公告编号 2024-005）。 二、本公告前十二个月内使用闲置自有资金购买理财产品的管理情况 | 受托方 | 产品类型 | 产品名称 | 收益 | 起息日 | | 到息日 | 金额 （万 | 是否赎 | 实际收 益（万 | | --- | --- | --- | ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 347,843,789.44, a decrease of 25.90% compared to CNY 469,428,507.08 in the same period last year[10]. - The net profit attributable to shareholders for the reporting period was CNY 33,335,808.28, down 29.71% from CNY 47,428,322.86 year-on-year[10]. - The basic earnings per share decreased to CNY 0.1007, a decline of 29.73% compared to CNY 0.1433 in the previous year[10]. - The net cash flow from operating activities was CNY 43,919,396.25, representing a significant drop of 62.23% from CNY 116,279,461.95 in the same period last year[10]. - The company reported a decrease of 45.04% in net profit after deducting non-recurring gains and losses, amounting to CNY 20,305,112.16 compared to CNY 36,945,048.36 in the previous year[10]. - The weighted average return on net assets was 1.52%, down from 2.18% in the previous year, reflecting a decline of 0.66%[10]. - The company reported a total of 330,951,600 shares outstanding, with 29.96% being restricted shares and 70.04% being unrestricted shares[50]. - The total comprehensive income for the first half of 2024 was CNY 34,933,284.97, down from CNY 45,953,590.56 in the same period of 2023[73]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,004,725,858.04, a decrease of 1.38% from CNY 3,046,722,440.31 at the end of the previous year[10]. - The net assets attributable to shareholders decreased to CNY 2,216,856,403.71, down 0.73% from CNY 2,233,163,335.43 at the end of the previous year[10]. - The company's total liabilities decreased to CNY 884,251,845.53 from CNY 1,007,982,736.36, reflecting a reduction of approximately 12.3%[69]. - Current liabilities totaled CNY 619,250,791.57, down 30.6% from CNY 891,777,181.55 in the previous year[69]. - Short-term borrowings decreased significantly from CNY 470,432,666.67 to CNY 320,266,477.79, a decrease of approximately 31.9%[64]. - Total liabilities decreased from CNY 714,301,698.53 to CNY 688,586,142.51, a decline of approximately 3.6%[64]. Investment and Cash Flow - Investment activities resulted in a net cash outflow of CNY 353,318,737.93, an increase of 455.95% compared to a net outflow of CNY 63,552,150.50 in the previous year[22]. - The company reported a net decrease in cash and cash equivalents of CNY 369,570,053.89, a decline of 541.77% from an increase of CNY 83,657,004.16 in the previous year[22]. - The company's cash and cash equivalents decreased to CNY 118,163,587.06 from CNY 487,733,640.95, representing a decline of approximately 75.8%[62]. - The total cash and cash equivalents at the end of the period were CNY 118,163,587.06, a decrease from CNY 426,920,881.92 at the end of the first half of 2023[75]. - The cash flow from operating activities generated a net amount of CNY 43,919,396.25, down from CNY 116,279,461.95 in the first half of 2023[74]. Business Operations and Strategy - The company has expanded its business model to include six major sectors, including traditional medicine and cosmetics, establishing a comprehensive ginseng industry chain[15]. - The company aims to enhance its market position through continuous collaboration with renowned universities and research institutions[15]. - The company is positioned to benefit from ongoing reforms in the healthcare system, which aim to improve the quality and accessibility of medical services[15]. - The company is committed to leveraging modern technology while rooting its operations in traditional culture to drive growth in the ginseng industry[15]. - The company has developed a complete range of products from ginseng roots to leaves, flowers, and fruits, becoming the first in the pharmaceutical industry to achieve full ginseng plant development[16]. - The company has cultivated over 10,000 acres of non-forest ginseng, all certified organic, and has developed two excellent varieties, "Yisheng Ginseng No. 1" and "Yisheng Ginseng No. 2," along with 14 patents and 2 technological achievements[16]. Research and Development - The company holds 20 invention patents, 5 design patents, and 4 utility model patents, showcasing its commitment to research and development[19]. - Research and development expenses for the first half of 2024 were CNY 9,552,824.22, slightly down from CNY 10,560,351.09 in the same period of 2023[69]. - The company has not reported any significant new product developments or technological advancements during this period[85]. Market and Industry Context - The pharmaceutical industry is recognized as a strategic sector crucial for national health and economic development, with a clear growth trend driven by increasing healthcare demands[14]. - The government has increased support for the pharmaceutical industry, promoting fair pricing and transparency in drug procurement[14]. - The company benefits from local sourcing of raw materials, ensuring quality and reducing procurement costs, particularly for ginseng and other medicinal herbs[20]. Environmental and Social Responsibility - The company is committed to enhancing its environmental management practices in response to stricter regulations and societal expectations[34]. - The company emphasizes environmental protection and has implemented measures to ensure compliance with relevant environmental laws and regulations[40]. - The company continues to focus on social responsibility and actively participates in charitable activities[41]. Risks and Challenges - The company faces various operational risks as detailed in the management discussion section, which investors should be aware of[1]. - The company faces risks related to industry policy adjustments, production cost increases, R&D challenges, inventory price declines, adverse drug reactions, and environmental compliance[32][34]. - The company has implemented measures to monitor and control drug quality throughout its lifecycle to mitigate risks associated with adverse drug reactions[33]. Shareholder Information - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[51]. - The company has not engaged in any significant related party transactions during the reporting period[45]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[42]. Accounting and Financial Reporting - The financial statements are prepared based on the going concern assumption, indicating no significant doubts about the company's ability to continue operations for at least 12 months[92]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial reports reflect a true and complete picture of its financial status[94]. - The financial reports comply with the disclosure requirements of the China Securities Regulatory Commission[94].

上市公司2024年6月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：吉林省集安益盛药业股份有限公司 金额单位：人民币元 附表 公司负责人：张益胜 主管会计工作的负责人：毕建涛 会计机构负责人：苏美华 1 | 非经营性资金占 用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司核算的 会计科目 | 2024年初占用 资金余额 | 2024年1-6月往来累计发 生金额（不含利息） | 2024年1-6月往来 资金的利息（如有 | 2024年度偿还 累计发生额 | 2024年6月末占 用资金余额 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | ） | | | | | | 现大股东及其附 | | | | | | | | | | 非经营性占用 | | 属企业 | | | | | | | | | | 非经营性占用 | | 小 计 | —— | —— | —— | | | | | | —— | —— | | 前大股东及其附 | | | | | | ...

证券代码：002566 证券简称：益盛药业 公告编号：2024-022 吉林省集安益盛药业股份有限公司 关于使用闲置自有资金购买理财产品到期赎回 并继续购买理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省集安益盛药业股份有限公司（以下简称"公司"）于 2024 年 5 月 20 日召开第八届董事会第十三次会议、第八届监事会第十三次会议，审议通过了《关 于使用闲置自有资金购买理财产品的议案》，为提高公司资金使用效率，合理利 用闲置自有资金，在保证日常经营资金需求和资金安全的前提下，公司及子公司 使用不超过 35,000 万元人民币的闲置自有资金购买理财产品。内容详见公司于 2024 年 5 月 21 日在指定信息披露媒体及巨潮资讯网（www.cninfo.com.cn）披 露的《关于使用闲置自有资金购买理财产品的公告》（公告编号 2024-019）。 二、本次使用闲置自有资金购买理财产品的基本情况 1、公司与上海国泰君安证券资产管理有限公司签署了《国泰君安私客尊享 FOF3067 号单一资产管理计划资产管理合同》，本合同主要条款如下（包括但 ...